BioCryst Pharma (BCRX) Posts Narrower than Expected Q1 Loss of 13c/Share; Reaffirms

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q1 EPS of ($0.13), $0.13 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $5.9 million.

BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance
• Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance